What question did this study set out to answer?

This study aims to assess treatment patterns and outcomes of chronic myelogenous leukemia in an underserved population.

December 8, 2025Blood

Chronic myelogenous leukemia: A real-world experience from a Los Angeles county safety net hospital

View Full Paper

Ask AI

Bookmark

Authors

DZDominick Zheng

Discussion

Member takes

Overview

Retrospective review shows treatment challenges in chronic myelogenous leukemia patients, indicating needs for better access and adherence strategies.

Key Points

This study aims to assess treatment patterns and outcomes of chronic myelogenous leukemia in an underserved population.
Retrospective chart review of patients diagnosed with chronic myelogenous leukemia between 2015 and 2024.
Patients had their BCR-ABL1 fusion gene detected using reverse transcription polymerase chain reaction.
Data on demographics, treatment responses, and discontinuation reasons were collected.
Median age at diagnosis was 47 years; 58.3% of patients were Hispanic.
46.5% of patients on first line treatment achieved major molecular response.
58.3% discontinued first line therapy, mainly due to intolerance or inadequate response.

Cite This Study

Dominick Zheng (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd69 https://doi.org/10.1182/blood-2025-1998

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Chronic myelogenous leukemia: A real-world experience from a Los Angeles county safety net hospital

View Full Paper

Ask AI

Bookmark

Authors

DZDominick Zheng

Discussion

Member takes

Overview

Retrospective review shows treatment challenges in chronic myelogenous leukemia patients, indicating needs for better access and adherence strategies.

Key Points

This study aims to assess treatment patterns and outcomes of chronic myelogenous leukemia in an underserved population.
Retrospective chart review of patients diagnosed with chronic myelogenous leukemia between 2015 and 2024.
Patients had their BCR-ABL1 fusion gene detected using reverse transcription polymerase chain reaction.
Data on demographics, treatment responses, and discontinuation reasons were collected.
Median age at diagnosis was 47 years; 58.3% of patients were Hispanic.
46.5% of patients on first line treatment achieved major molecular response.
58.3% discontinued first line therapy, mainly due to intolerance or inadequate response.

Cite This Study

Dominick Zheng (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd69 https://doi.org/10.1182/blood-2025-1998

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark